Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine
Go back to Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 11.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.96 | 52 Week High | $7.95 | |||
| Open | $11.96 | 52 Week Low | $0.40 | |||
| Day High | $11.96 | P/E | N/A | |||
| Day Low | $11.96 | EPS | $-5.33 | |||
| Volume | 104 | |||||
